PDCD1 and non-small cell lung carcinoma: Our study not only included αβ T cells but also investigated the changes in the levels of cell surface coinhibitory molecules (PD-1 and TIM-3) in major subsets of γδ T cells before and after PD-1 inhibitor therapy in patients with NSCLC.